Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Comment by attila9on Jul 05, 2004 10:36am

184 Views

Post# 7674484

RE: Shareholder Responsibility

Perhaps you would like to enlighten us all as to when anybody can remember anybody at COT acting responsibly???I certainly can't recall the last time.If they were responsible they would be coming clean with their shareholders as to the financial staus of COT,contract status, & just what & how they plan on spending this new found wealth.I believe as many do that it will go into the pockets of management & the demise of COT will happen regardless of what we vote on.This is a done turkey.JMHO of course but i'm from Missouri "show me".TRUST is EARNED not GIVEN!!!!!!!!!COT management has yet to earn anybobies trust in my opinion!!!!!!

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload